TY - JOUR
T1 - Molecular dynamic simulation analysis on marine fungi compounds against EGFR and VEGFR-2 inhibitory activity in non-small cell lung cancer
AU - Yanuar, Arry
AU - Chavarina, Kinanti Khansa
AU - Syahdi, Rezi Riadhi
N1 - Publisher Copyright:
© 2018 EManuscript Technologies. All rights reserved.
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Introduction: According to International Agency for Research on Cancer (IARC), the number of lung cancer patients has reached 1.8 million lives, and 85% of the number contribute to non-small cell lung cancer. In the past years, research on targeted therapy has been developed due to its efficacy and a small number of side effects. Research on marine fungi compounds has not been explored to non-small cell lung cancer therapy. Methods: This research uses molecular dynamics simulation method to marine fungi compounds that have been docked to EGFR (FU0015, FU0051, FU0202) and VEGFR-2 (FU0033) as antiproliferative and antiangiogenetic agent by inhibition activity using AutoDock and AMBER at 300K and 310K temperature using EGFR (Gefitinib, Erlotinib, and Imatinib) and VEGFR-2 (Nicotinamide and Vatalanib) as reference standards. Results: Molecular dynamics results for EGFR inhibitors at 310K shows the best MMGBSA free energy and hydrogen occupancy in FU0051 (-43.72 kcal/mol; 98.80%) followed by FU0202 (-31.64 kcal/mol; 43.35%), and FU0015 (-15.55 kcal/mol; 3.35%). FU0033 fungi as a material for VEGFR-2 inhibitor shows higher MMGBSA free energy in comparison to its reference standards and low hydrogen occupancy (0.15%) at 310K. Conclusion:This research shows that FU0051 and FU0202 have potential to be an antiproliferative agent candidate, hence in vitro test should be obtained.
AB - Introduction: According to International Agency for Research on Cancer (IARC), the number of lung cancer patients has reached 1.8 million lives, and 85% of the number contribute to non-small cell lung cancer. In the past years, research on targeted therapy has been developed due to its efficacy and a small number of side effects. Research on marine fungi compounds has not been explored to non-small cell lung cancer therapy. Methods: This research uses molecular dynamics simulation method to marine fungi compounds that have been docked to EGFR (FU0015, FU0051, FU0202) and VEGFR-2 (FU0033) as antiproliferative and antiangiogenetic agent by inhibition activity using AutoDock and AMBER at 300K and 310K temperature using EGFR (Gefitinib, Erlotinib, and Imatinib) and VEGFR-2 (Nicotinamide and Vatalanib) as reference standards. Results: Molecular dynamics results for EGFR inhibitors at 310K shows the best MMGBSA free energy and hydrogen occupancy in FU0051 (-43.72 kcal/mol; 98.80%) followed by FU0202 (-31.64 kcal/mol; 43.35%), and FU0015 (-15.55 kcal/mol; 3.35%). FU0033 fungi as a material for VEGFR-2 inhibitor shows higher MMGBSA free energy in comparison to its reference standards and low hydrogen occupancy (0.15%) at 310K. Conclusion:This research shows that FU0051 and FU0202 have potential to be an antiproliferative agent candidate, hence in vitro test should be obtained.
KW - EGFR
KW - Lung cancer
KW - Marine fungi compounds
KW - Molecular dynamics
KW - VEGFR-2
UR - http://www.scopus.com/inward/record.url?scp=85050266448&partnerID=8YFLogxK
U2 - 10.5530/jyp.2018.2s.6
DO - 10.5530/jyp.2018.2s.6
M3 - Article
AN - SCOPUS:85050266448
SN - 0975-1483
VL - 10
SP - s25-s31
JO - Journal of Young Pharmacists
JF - Journal of Young Pharmacists
IS - 2
ER -